Sinopharm Modern Pharmaceuticals’ subsidiary’s Amikacin Sulfate Injection passed the consistency evaluation
May 15, 2025
Source: drugdu
67
On May 13, Sinopharm Modern issued an announcement that recently, its wholly-owned subsidiary Sinopharm Rongsheng Pharmaceutical Co., Ltd. received the "Notice of Approval of Drug Supplementary Application" approved and issued by the National Drug Administration, approving Amikacin Sulfate Injection to pass the generic drug quality and efficacy consistency evaluation.
The announcement mentioned that the sales of amikacin sulfate injection in public medical institutions across the country will be 233 million yuan in 2024. So far, Sinopharm Rongsheng has invested approximately 4.59 million yuan (unaudited) in research and development for the consistency evaluation of the drug.
In the first quarter of 2025, Sinopharm Modern achieved revenue of 2.607 billion yuan and net profit attributable to shareholders of the parent company of 361 million yuan.
https://finance.eastmoney.com/a/202505133403270474.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
- LH-1801 project enters Phase III clinical trial July 7, 2025
- The new generation of DNA biosynthesis technology is moving towards industrialization July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
